



BÖLÜM 5

UYARICI MADDELER VE KULLANIM BOZUKLUKLARI

Dilek BAKIŞ AKSOY¹

AMFETAMİNLER VE AMFETAMİN BENZERİ UYARICILAR

Tarihçe

Ephedra, 5000 yılı aşkın zamanda geleneksel Çin tıbbında kullanılan ve Ma-hu-ang olarak adlandırılan *Ephedra sinica* bitkisinden elde edilir. 1885 yılında ephedrada bulunan aktif alkaloid olan efedrin üretilmiştir. Sentetik bir efedrin olan amfetamin ve metamfetamin, merkezi sinir stimülasyonu, bronkodilatasyon veya nazal vazokonstriksiyon gibi farmasötik amaçlarla efedrinden geliştirildi (1).

Sentetik uyarıcıların ilki olan amfetamin 1887’de izole edilmiştir. İlk olarak 1930’larda amfetamin fenilizopropilamin içeren ve reçetesiz satılan nazal dekonjestan (Bezedrine inhaler) olarak popüler hale geldi. Ardından yorgunluk, narcolepsi ve depresyon gibi klinik uygulamalarda kullanılmaya başlandı (2). Kolay erişilmesi ve popüleritesinin artması yanlış kullanımlara yol açtığından 1957’de reçetesiz (tezgahüstü) ilaç kullanımını yasaklandı.

Metamfetamin 1919’da izole edildi. Metamfetamin kullanımını 1960’ların sonlarına doğru zirveye ulaştı. 1971’de yasal düzenlemelerle amfetamin ve metamfetaminin popüleritesi bir süreliğine azaldı. İkinci dünya savaşında uzun süre uyanık kalmak için reçeteli suistimal edilen metamfetamin veya amfetamin kul-

¹ Uzm. Dr., Hatay Eğitim Araştırma Hastanesi Psikiyatri Kliniği, dlkbks_dok@hotmail.com

KAYNAKLAR

1. Hunt D, Kuck S, Truitt L. *Methamphetamine Use: Lessons Learned*. Cambridge, MA: Abt Associates Inc.; 2006. (Contract No. 209730)
2. Rasmussen N. Making the first anti-depressant: amphetamine in American medicine, 1929-1950. *Journal of the History of Medicine and Allied Sciences*. 2006;61(3):288-323. doi.org/10.1093/jhmas/jrj039
3. Goode E. *Drugs in American society*. 6th ed. New York: McGraw-Hill; 2005.
4. Vearrier D, Greenberg MI, Miller SN, et al. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. *Disease-a-Month*. 2012;58:38-89. doi:10.1016/j.disamonth.2011.09.004
5. Maxwell JC, Brecht M-L. Methamphetamine: here we go again? *Addictive Behaviors*. 2011;36(12): 1168-1173. doi.org/10.1016/j.addbeh.2011.07.017
6. Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: A Systematic Review. *CNS Drugs*. 2020; 34:337-365. doi.org/10.1007/s40263-020-00711-x
7. Substance Abuse and Mental Health Services Administration 2020. *Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health*. (23/01/2022 tarihinde <https://www.samhsa.gov/data/> adresinden indirilmiştir.)
8. Avrupa Uyuşturucu ve Uyuşturucu Bağımlılığını İzleme Merkezi 2021. *Avrupa Uyuşturucu Raporu 2021: Eğilimler ve Gelişmeler*. (24/01/2022 tarihinde doi:10.2810/384120 adresinden ulaşılmıştır.)
9. United Nations Office on Drugs and Crime 2021. *World Drug Report 2021*. (25/01/2022 tarihinde www.unodc.org/unodc/en/data-and-analysis/wdr2021.html adresinden ulaşılmıştır.)
10. Substance Abuse and Mental Health Service Administration 2018-2019. *National survey of drug use and health*. (01/02/2021 tarihinde www.samhsa.gov adresinden ulaşılmıştır.)
11. Docherty JR, Alsufyani HA. Pharmacology of Drugs Used as Stimulants. *The Journal of Clinical Pharmacology*. 2021;61(2):53-69. doi: 10.1002/jcph.1918
12. Fleckenstein AE, Volz TJ, Riddle EL, et al. New Insights into the Mechanism of Action of Amphetamines. *The Annual Review of Pharmacology and Toxicology*. 2007;47:681-698. doi.org/10.1146/annurev.pharmtox.47.120505.105140.
13. Howell LL, Kimmel HL. Monoamine transporters and psychostimulant addiction. *Biochemical Pharmacology*. 2008;75(1):196-217. doi.org/10.1016/j.bcp.2007.08.003
14. Sulzer D, Sonders MS, Poulsen NW, et al. Mechanisms of neurotransmitter release by amphetamines: a review. *Progress in Neurobiology*. 2005;75(6):406-433. doi:10.1016/j.pneurobio.2005.04.003
15. Katzung BG. *Basic and Clinical Pharmacology*. 8th ed. New York: Lange Medical/McGraw-Hill; 2001.
16. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. *Addiction*. 2009;104(7):1085-1099.
17. Ciccarone D. Stimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy. *Primary Care: Clinics in Office Practice*. 2011;38(1):41-58. doi: 10.1016/j.pop.2010.11.004
18. European Monitoring Centre for Drugs and Drug Addiction 2014. *Exploring methamphetamine trends in Europe*. (13/03/2018 tarihinde http://www.emcdda.europa.eu/system/files/publications/787/TDAU14001ENN_460800.pdf adresinden ulaşılmıştır.)
19. Faraone SV. The Pharmacology of Amphetamine and Methylphenidate: Relevance to the Neurobiology of Attention-Deficit/Hyperactivity Disorder and Other Psychiatric Comorbidities. *Neuroscience & Biobehavioral Reviews*. 2018;87:255-270. doi:10.1016/j.neubiorev.2018.02.001

20. Evren C, Bozkurt M. Metamfetamin Güncellemesi: Son Zamanlarda Karşılaştığımız Eski Bir Problem. *Dusunen Adam The Journal of Psychiatry and Neurological Sciences*. 2018; 31: 1-10 doi:10.5350/DAJPN20183101001.
21. Kudlacek O, Hofmaier T, Luf A et al. Cocaine adulteration. *Journal of Chemical Neuroanatomy*. 2017;1(83-84):75–81. doi:10.1016/j.jchemneu.2017.06.001
22. Frances RJ, Miller SI, Mack AH. *Clinical Textbook of Addictive Disorders*. Third ed. New York: The Guilford Press; 2005.
23. Barnett G, Hawks R, Resnick R J. Cocaine pharmacokinetics in humans. *Journal of Ethnopharmacology*. 1981;3(2-3):353-366. doi:10.1016/0378-8741(81)90063-5.
24. Jenkins AJ, Keenan RM, Henningfield JE. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. *Journal of Analytical Toxicology*. 2002;26(7):382-392.
25. Brandt L, Chao T, Comer SD, et al. Pharmacotherapeutic strategies for treating cocaine use disorder—what do we have to offer? *Addiction*. 2021;116(4): 694–710. doi: 10.1111/add.15242
26. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. *Biochemical Pharmacology* .2008;75(1): 218-265.
27. Williams MJ, Adinoff B. The role of acetylcholine in cocaine addiction. *Neuropsychopharmacology*. 2008;33(8): 1779-1797.
28. Al Suwaidi J, Ali WM, Aleryani SL. Cardiovascular complications of Khat. *Clinica Chimica Acta*. 2013; 419: 11-14. doi:10.1016/j.cca.2013.01.007.
29. Iversen L, White M, Treble R. Designer psychostimulants: Pharmacology and differences. *Neuropharmacology*. 2014;87:59-65. doi:10.1016/j.neuropharm.2014.01.015
30. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
31. Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. *Current HIV/AIDS Reports*. 2005;2(4):194–199.
32. Gossop M, Griffiths P, Powis B, et al. Cocaine: patterns of use, route of administration, and severity of dependence. *The British Journal of Psychiatry*. 1994;164(5):660–664.
33. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. *Pharmacotherapy*. 2006; 26(8): 1148-1156. doi:10.1592/phco.26.8.1148.
34. Bonate PL, Swann A, Silverman PB. Context-dependent cross-sensitization between cocaine and amphetamine. *Life Sciences*. 1997; 60(1): PL1-7. doi:10.1016/S0024-3205(96)00591-7.
35. Mahoney JJ, Kalechstein AD, , De La Garza R, et al. Presence and persistence of psychotic symptoms in cocaine- versus methamphetamine-dependent participants. *The American Journal On Addiction*. 2008; 17(2): 83-98. doi:10.1080/10550490701861201.
36. Coffey SF, Dansky BS, Carrigan MH, et al. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. *Drug and Alcohol Dependence*. 2000; 59(3): 277-286. doi.org/10.1016/S0376-8716(99)00126-X.
37. Kılıç FS. Bağımlılık ve Uyarıcı Maddeler. *Osmangazi Journal of Medicine*. 2016; 38 (Special Issue 1): 55-60. DOI: <http://dx.doi.org/10.20515/otd.50661>.
38. Angrist B, Engel J, Oreland L, et al. *Clinical effects of central nervous system stimulants: a selective update*. New York: Raven Press; 1987.
39. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, et al. Methamphetamine Treatment Project. Risk factors for suicide attempts in methamphetamine-dependent patients. *American journal on addictions*. 2008;17(1):24-27.
40. Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. *Metabolic Brain Disease*. 2014;29:351–357.
41. Gouzoulis-Mayfrank E, Härtel-Petri R, Hamdorf W, et al. Methamphetamine-related disorders. *Deutsches Ärzteblatt international*. 2017;114:455-641.

42. Richards JR, Albertson TE, Derlet RW, et al. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. *Drug and Alcohol Dependence*. 2015;150:1-13.
43. Paulus MP, Stewart JL. Methamphetamine Use Disorder: The Next Addiction Crisis. *JAMA Psychiatry*. 2020;77(9):959-966. doi: 10.1001/jamapsychiatry.2020.0246
44. Phillips KA, Epstein DH, Preston KL. Psychostimulant addiction treatment. *Neuropharmacology*. 2014; 87: 150-160. doi:10.1016/j.neuropharm.2014.04.002
45. Ronsley C, Nolan S, Knight R, et al. Treatment of stimulant use disorder: A systematic review of reviews. *PLoS ONE*. 2020; 15(6): e0234809. doi:10.1371/journal.pone.0234809
46. De Crescenzo F, Ciabattini M, D'Alò GL, et al. Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis. *PLoS medicine*. 2018;15(12):e1002715.
47. Newton TF, Kalechstein AD, Duran S, et al. Methamphetamine abstinence syndrome: preliminary findings. *American Journal on Addictions*. 2004;13(3):248-255.
48. Zorick T, Nestor L, Miotto K, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. *Addiction*. 2010; 105(10):1809-1818.
49. Indave BI, Minozzi S, Pani PP, et al. Antipsychotic medications for cocaine dependence. *Cochrane Database of Systematic Reviews*. 2016; 3(3):CD006306.doi:10.1002/14651858.CD006306.pub3.
50. Pani PP, Trogu E, Vacca R, et al. Disulfiram for the treatment of cocaine dependence. *Cochrane Database of Systematic Reviews*. 2010;(1):Cd007024
51. Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. *JAMA Psychiatry*.2013;70(12):1338-1346.
52. Elkashef A, Holmes TH, Bloch DA, et al. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. *Addiction*. 2005; 100(1):91-101.
53. Brensler M, Heinzerling KG, Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: An update. *Drug and Alcohol Dependence*. 2013;32(5):449-460. doi:10.1111/dar.12048
54. Xiaoshan T, Junjie Y, Wenqing W, et al. Immunotherapy for treating methamphetamine, heroin and cocaine use disorders. *Drug Discovery Today*. 2020;25(3):610-619.
55. Chan B, Kondo K, Freeman M, et al. Pharmacotherapy for cocaine use disorder—a systematic review and meta-analysis. *Journal of general internal medicine*. 2019; 34(12): 2858-2873. doi:10.1007/s11606-019-05074-8
56. Courtney KE, Ray LA. Methamphetamine: An Update on Epidemiology, Pharmacology, Clinical Phenomenology, and Treatment Literature. *Drug and Alcohol Dependence*. 2014;1:11-21. doi:10.1016/j.drugalcdep.2014.08.003